Neutrophil-derived proteases in the microenvironment of pancreatic cancer –active players in tumor progression

International Journal of Biological Sciences

Volumn 12, Issue 3, 2016, Pages 302-313

  Felix, Klaus ^a   Gaida, Matthias M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Inflammation; Microenvironment; Neutrophils proteinases; Pancreatic cancer

Indexed keywords

PEPTIDE HYDROLASE;

ANIMAL; HUMAN; METABOLISM; NEUTROPHIL; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; NEUTROPHILS; PANCREATIC NEOPLASMS; PEPTIDE HYDROLASES; TUMOR MICROENVIRONMENT;

EID: 84957543969     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.14996     Document Type: Review

References (140)

1. R V: Die krankhaften Geschwülste. Berlin: August Hirschwald; 1864-1865.
2. Coussens LM, Zitvogel L, Palucka AK: Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013, 339:286-291.
3. Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, Lohr JM, Friess H: Pancreatic cancer microenvironment. Int J Cancer 2007, 121:699-705.
4. Takeuchi S, Baghdadi M, Tsuchikawa T, Wada H, Nakamura T, Abe H, Nakanishi S, Usui Y, Higuchi K, Takahashi M, et al: Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer. Cancer Res 2015, 75:2629-2640.
5. Mason SD, Joyce JA: Proteolytic networks in cancer. Trends Cell Biol 2011, 21:228-237.
6. Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
7. Edwards DR, Handsley MM, Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med 2008, 29:258-289.
8. Murphy G: The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008, 8:929-941.
9. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
10. Phillipson M, Kubes P: The neutrophil in vascular inflammation. Nat Med 2011, 17:1381-1390.
11. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A: Neutrophil function: from mechanisms to disease. Annu Rev Immunol 2012, 30:459-489.
12. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268.
13. Piccard H, Muschel RJ, Opdenakker G: On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 2012, 82:296-309.
14. Dumitru CA, Lang S, Brandau S: Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol 2013, 23:141-148.
15. Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S: Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 2012, 61:1155-1167.
16. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A: Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992, 80:2012-2020.
17. Yoshimura T, Takahashi M: IFN-gamma-mediated survival enables human neutrophils to produce MCP-1/CCL2 in response to activation by TLR ligands. J Immunol 2007, 179:1942-1949.
18. Peters NC, Egen JG, Secundino N, Debrabant A, Kimblin N, Kamhawi S, Lawyer P, Fay MP, Germain RN, Sacks D: In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 2008, 321:970-974.
19. Scapini P, Laudanna C, Pinardi C, Allavena P, Mantovani A, Sozzani S, Cassatella MA: Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19. Eur J Immunol 2001, 31:1981-1988.
20. Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ, Anderson KL, Dattilo BM, Dunman PM, Gerads R, et al: Metal chelation and inhibition of bacterial growth in tissue abscesses. Science 2008, 319:962-965.
21. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM: Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
22. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V: Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010, 22:238-244.
23. Brandau S, Moses K, Lang S: The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? Semin Cancer Biol 2013, 23:171-182.
24. Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, Horng W, Fridlender G, Bayuh R, Worthen GS, Albelda SM: Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One 2012, 7:e31524.
25. Fridlender ZG, Albelda SM: Tumor-associated neutrophils: friend or foe? Carcinogenesis 2012, 33:949-955.
26. Gregory AD, Houghton AM: Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011, 71:2411-2416.
27. Sparmann A, Bar-Sagi D: Ras oncogene and inflammation: partners in crime. Cell Cycle 2005, 4:735-736.
28. Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, Mayaud C, Milleron B, Baud L, Cadranel J: Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 1998, 152:83-92.
29. Gaida MM, Gunther F, Wagner C, Friess H, Giese NA, Schmidt J, Hansch GM, Wente MN: Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections. Clin Exp Immunol 2008, 154:216-223.
30. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA: The neutrophil as a cellular source of chemokines. Immunol Rev 2000, 177:195-203.
31. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N: Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013, 108:914-923.
32. Reid MD, Basturk O, Thirabanjasak D, Hruban RH, Klimstra DS, Bagci P, Altinel D, Adsay V: Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol 2011, 24:1612-1619.
33. Welch DR, Schissel DJ, Howrey RP, Aeed PA: Tumor-elicited polymorphonuclear cells, in contrast to "normal" circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci U S A 1989, 86:5859-5863.
34. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009, 27:4709-4717.
35. Wislez M, Rabbe N, Marchal J, Milleron B, Crestani B, Mayaud C, Antoine M, Soler P, Cadranel J: Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res 2003, 63:1405-1412.
36. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P: The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001, 97:339-345.
37. Kindzelskii AL, Petty HR: Early membrane rupture events during neutrophil-mediated antibody-dependent tumor cell cytolysis. J Immunol 1999, 162:3188-3192.
38. Aeed PA, Nakajima M, Welch DR: The role of polymorphonuclear leukocytes (PMN) on the growth and metastatic potential of 13762NF mammary adenocarcinoma cells. Int J Cancer 1988, 42:748-759.
39. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A: Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007, 18:171-182.
40. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U: Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999, 155:537-547.
41. Yang JJ, Hu ZG, Shi WX, Deng T, He SQ, Yuan SG: Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis. World J Gastroenterol 2015, 21:2807-2815.
42. Mueller MD, Lebovic DI, Garrett E, Taylor RN: Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil Steril 2000, 74:107-112.
43. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL: Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 2005, 65:8896-8904.
44. Mangerich A, Knutson CG, Parry NM, Muthupalani S, Ye W, Prestwich E, Cui L, McFaline JL, Mobley M, Ge Z, et al: Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. Proc Natl Acad Sci U S A 2012, 109:E1820-1829.
45. Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 117:1155-1166.
46. Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, Bourdeau F, Kubes P, Ferri L: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest 2013.
47. Hajjar E, Broemstrup T, Kantari C, Witko-Sarsat V, Reuter N: Structures of human proteinase 3 and neutrophil elastase--so similar yet so different. FEBS J 2010, 277:2238-2254.
48. Wiedow O, Muhle K, Streit V, Kameyoshi Y: Human eosinophils lack human leukocyte elastase. Biochim Biophys Acta 1996, 1315:185-187.
49. Weinrauch Y, Drujan D, Shapiro SD, Weiss J, Zychlinsky A: Neutrophil elastase targets virulence factors of enterobacteria. Nature 2002, 417:91-94.
50. Gaida MM, Steffen TG, Gunther F, Tschaharganeh DF, Felix K, Bergmann F, Schirmacher P, Hansch GM: Polymorphonuclear neutrophils promote dyshesion of tumor cells and elastase-mediated degradation of E-cadherin in pancreatic tumors. Eur J Immunol 2012, 42:3369-3380.
51. Grosse-Steffen T, Giese T, Giese N, Longerich T, Schirmacher P, Hansch GM, Gaida MM: Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase. Clin Dev Immunol 2012, 2012:720768.
52. Yamanouchi H, Fujita J, Hojo S, Yoshinouchi T, Kamei T, Yamadori I, Ohtsuki Y, Ueda N, Takahara J: Neutrophil elastase: alpha-1-proteinase inhibitor complex in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis. Eur Respir J 1998, 11:120-125.
53. Sun Z, Yang P: Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 2004, 5:182-190.
54. Mainardi CL, Hasty DL, Seyer JM, Kang AH: Specific cleavage of human type III collagen by human polymorphonuclear leukocyte elastase. J Biol Chem 1980, 255:12006-12010.
55. Mainardi CL, Dixit SN, Kang AH: Degradation of type IV (basement membrane) collagen by a proteinase isolated from human polymorphonuclear leukocyte granules. J Biol Chem 1980, 255:5435-5441.
56. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A: Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
57. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A: Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 2010, 191:677-691.
58. Kamohara H, Sakamoto K, Mita S, An XY, Ogawa M: Neutrophil elastase inhibitor (ONO-5046.Na) suppresses the proliferation, motility and chemotaxis of a pancreatic carcinoma cell line, Capan-1. Res Commun Mol Pathol Pharmacol 1997, 98:103-108.
59. Nozawa F, Hirota M, Okabe A, Shibata M, Iwamura T, Haga Y, Ogawa M: Elastase activity enhances the adhesion of neutrophil and cancer cells to vascular endothelial cells. J Surg Res 2000, 94:153-158.
60. Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, Barnes CM, O'Reilly MS, Folkman J, Pirie-Shepherd SR: Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 2001, 61:7298-7304.
61. Sato T, Takahashi S, Mizumoto T, Harao M, Akizuki M, Takasugi M, Fukutomi T, Yamashita J: Neutrophil elastase and cancer. Surg Oncol 2006, 15:217-222.
62. Bergin DA, Greene CM, Sterchi EE, Kenna C, Geraghty P, Belaaouaj A, Taggart CC, O'Neill SJ, McElvaney NG: Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. J Biol Chem 2008, 283:31736-31744.
63. Voynow JA, Fischer BM, Zheng S: Proteases and cystic fibrosis. Int J Biochem Cell Biol 2008, 40:1238-1245.
64. Witko-Sarsat V, Lesavre P, Lopez S, Bessou G, Hieblot C, Prum B, Noel LH, Guillevin L, Ravaud P, Sermet-Gaudelus I, et al: A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999, 10:1224-1233.
65. Wang Y, Xiao Y, Zhong L, Ye D, Zhang J, Tu Y, Bornstein SR, Zhou Z, Lam KS, Xu A: Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with beta-cell autoimmunity in patients with type 1 diabetes. Diabetes 2014, 63:4239-4248.
66. Ganss R, Hanahan D: Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 1998, 58:4673-4681.
67. Tan GJ, Peng ZK, Lu JP, Tang FQ: Cathepsins mediate tumor metastasis. World J Biol Chem 2013, 4:91-101.
68. Sulpizio S, Franceschini N, Piattelli A, Di Sebastiano P, Innocenti P, Selvaggi F: Cathepsins and pancreatic cancer: the 2012 update. Pancreatology 2012, 12:395-401.
69. Michl P: Targeting cathepsins: a new glimmer of hope for pancreatic cancer therapy? Gut 2012, 61:790-791.
70. Wiedow O, Meyer-Hoffert U: Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Intern Med 2005, 257:319-328.
71. Padrines M, Wolf M, Walz A, Baggiolini M: Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3. FEBS Lett 1994, 352:231-235.
72. Chertov O, Ueda H, Xu LL, Tani K, Murphy WJ, Wang JM, Howard OM, Sayers TJ, Oppenheim JJ: Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med 1997, 186:739-747.
73. Shamamian P, Pocock BJ, Schwartz JD, Monea S, Chuang N, Whiting D, Marcus SG, Galloway AC, Mignatti P: Neutrophil-derived serine proteinases enhance membrane type-1 matrix metalloproteinase-dependent tumor cell invasion. Surgery 2000, 127:142-147.
74. Bird PI: Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Immunol Cell Biol 1999, 77:47-57.
75. Kudo T, Kigoshi H, Hagiwara T, Takino T, Yamazaki M, Yui S: Cathepsin G, a neutrophil protease, induces compact cell-cell adhesion in MCF-7 human breast cancer cells. Mediators Inflamm 2009, 2009:850-940.
76. Pan S, Chen R, Stevens T, Bronner MP, May D, Tamura Y, McIntosh MW, Brentnall TA: Proteomics portrait of archival lesions of chronic pancreatitis. PLoS One 2011, 6:e27574.
77. Yamaguchi N, Yamamura Y, Koyama K, Ohtsuji E, Imanishi J, Ashihara T: Characterization of new human pancreatic cancer cell lines which propagate in a protein-free chemically defined medium. Cancer Res 1990, 50:7008-7014.
78. Basso D, Millino C, Greco E, Romualdi C, Fogar P, Valerio A, Bellin M, Zambon CF, Navaglia F, Dussini N, et al: Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut 2004, 53:1159-1166.
79. Dawelbait G, Winter C, Zhang Y, Pilarsky C, Grutzmann R, Heinrich JC, Schroeder M: Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data. Bioinformatics 2007, 23:i115-124.
80. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, Kilbride M, Breitbart RE, Chun M, Schonbeck U: Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001, 104:1899-1904.
81. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, Overall CM, Shapiro SD, Lopez-Otin C: Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003, 35:252-257.
82. Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V: Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation 2003, 71:114-125.
83. Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN, Hay JG: Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 2007, 15:1982-1990.
84. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004, 10:2832-2845.
85. Muhs BE, Patel S, Yee H, Marcus S, Shamamian P: Increased matrix metalloproteinase expression and activation following experimental acute pancreatitis. J Surg Res 2001, 101:21-28.
86. Yokota T, Denham W, Murayama K, Pelham C, Joehl R, Bell RH, Jr.: Pancreatic stellate cell activation and MMP production in experimental pancreatic fibrosis. J Surg Res 2002, 104:106-111.
87. Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
88. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR: Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 2002, 160:1745-1754.
89. Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, Lele SM, Ouellette M, Pour PM, Sasson AR, et al: Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 2008, 98:1540-1547.
90. Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, van der Reijden JJ, Hanemaaijer R, Griffioen G, Lamers CB, Verspaget HW: Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 2007, 43:1869-1876.
91. Tschesche H, Zolzer V, Triebel S, Bartsch S: The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 2001, 268:1918-1928.
92. Nethery A, O'Grady RL: Identification of a metalloproteinase co-purifying with rat tumour collagenase and the characteristics of fragments of both enzymes. Biochim Biophys Acta 1989, 994:149-160.
93. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG: Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991, 266:7870-7875.
94. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96:2673-2681.
95. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, Filep JG: Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J 2001, 15:2230-2240.
96. Opdenakker G, Van den Steen PE, Van Damme J: Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001, 22:571-579.
97. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G: Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995, 62:407-413.
98. Koshiba T, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee JU, Doi R, Arii S, Imamura M: Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998, 82:642-650.
99. Bramhall SR, Stamp GW, Dunn J, Lemoine NR, Neoptolemos JP: Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996, 73:972-978.
100. Lekstan A, Lampe P, Lewin-Kowalik J, Olakowski M, Jablonska B, Labuzek K, Jedrzejowska-Szypulka H, Olakowska E, Gorka D, Filip I, Dranka-Bojarowska D: Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma. J Physiol Pharmacol 2012, 63:589-599.
101. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, Szmitkowski M: Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009, 38:613-618.
102. Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003, 3:422-433.
103. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
104. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y: Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002, 277:36288-36295.
105. Nozawa H, Chiu C, Hanahan D: Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 2006, 103:12493-12498.
106. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005, 169:681-691.
107. Bausch D, Pausch T, Krauss T, Hopt UT, Fernandez-del-Castillo C, Warshaw AL, Thayer SP, Keck T: Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis 2011, 14:235-243.
108. Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, Friess H, Kleeff J: ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med 2007, 11:1162-1174.
109. Gaida MM, Haag N, Gunther F, Tschaharganeh DF, Schirmacher P, Friess H, Giese NA, Schmidt J, Wente MN: Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int J Mol Med 2010, 26:281-288.
110. Pruessmeyer J, Hess FM, Alert H, Groth E, Pasqualon T, Schwarz N, Nyamoya S, Kollert J, van der Vorst E, Donners M, et al: Leukocytes require ADAM10 but not ADAM17 for their migration and inflammatory recruitment into the alveolar space. Blood 2014, 123:4077-4088.
111. Roychaudhuri R, Hergrueter AH, Polverino F, Laucho-Contreras ME, Gupta K, Borregaard N, Owen CA: ADAM9 is a novel product of polymorphonuclear neutrophils: regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury. J Immunol 2014, 193:2469-2482.
112. Amendola RS, Martin AC, Selistre-de-Araujo HS, Paula-Neto HA, Saldanha-Gama R, Barja-Fidalgo C: ADAM9 disintegrin domain activates human neutrophils through an autocrine circuit involving integrins and CXCR 2. J Leukoc Biol 2015.
113. Gomez-Gaviro M, Dominguez-Luis M, Canchado J, Calafat J, Janssen H, Lara-Pezzi E, Fourie A, Tugores A, Valenzuela-Fernandez A, Mollinedo F, et al: Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol 2007, 178:8053-8063.
114. Bell JH, Herrera AH, Li Y, Walcheck B: Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc Biol 2007, 82:173-176.
115. Asayesh A, Alanentalo T, Khoo NK, Ahlgren U: Developmental expression of metalloproteases ADAM 9, 10, and 17 becomes restricted to divergent pancreatic compartments. Dev Dyn 2005, 232:1105-1114.
116. Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S, Fabbi M: The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 2007, 5:1246-1253.
117. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, et al: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 2009, 101:457-464.
118. Stocker W, Bode W: Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr Opin Struct Biol 1995, 5:383-390.
119. Krampert M, Kuenzle S, Thai SN, Lee N, Iruela-Arispe ML, Werner S: ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells. J Biol Chem 2005, 280:23844-23852.
120. Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Kobayashi H, Koizumi M, et al: Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res 2001, 7:3437-3443.
121. Iversen LF, Kastrup JS, Bjorn SE, Rasmussen PB, Wiberg FC, Flodgaard HJ, Larsen IK: Structure of HBP, a multifunctional protein with a serine proteinase fold. Nat Struct Biol 1997, 4:265-268.
122. Linder A, Soehnlein O, Akesson P: Roles of heparin-binding protein in bacterial infections. J Innate Immun 2010, 2:431-438.
123. Olofsson AM, Vestberg M, Herwald H, Rygaard J, David G, Arfors KE, Linde V, Flodgaard H, Dedio J, Muller-Esterl W, Lundgren-Akerlund E: Heparin-binding protein targeted to mitochondrial compartments protects endothelial cells from apoptosis. J Clin Invest 1999, 104:885-894.
124. Wang L, Liu Z, Dong Z, Pan J, Ma X: Azurocidin-induced inhibition of oxygen metabolism in mitochondria is antagonized by heparin. Exp Ther Med 2014, 8:1473-1478.
125. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015, 65:5-29.
126. Hess KR, Abbruzzese JL: Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol 2001, 19:3445-3446.
127. Saif MW: Anti-angiogenesis therapy in pancreatic carcinoma. JOP 2006, 7:163-173.
128. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
129. McCawley LJ, Matrisian LM: Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001, 13:534-540.
130. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R: Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003, 3:589-601.
131. Dufour A, Sampson NS, Zucker S, Cao J: Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol 2008, 217:643-651.
132. Dufour A, Zucker S, Sampson NS, Kuscu C, Cao J: Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem 2010, 285:35944-35956.
133. Redondo-Munoz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hernandez del Cerro M, Roderfeld M, Roeb E, Opdenakker G, Garcia-Marco JA, Garcia-Pardo A: Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010, 17:160-172.
134. Funel N, Costa F, Pettinari L, Taddeo A, Sala A, Chiriva-Internati M, Cobos E, Colombo G, Milzani A, Campani D, et al: Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. Pancreatology 2010, 10:545-552.
135. Dufour A, Sampson NS, Li J, Kuscu C, Rizzo RC, Deleon JL, Zhi J, Jaber N, Liu E, Zucker S, Cao J: Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res 2011, 71:4977-4988.
136. Moroy G, Alix AJ, Sapi J, Hornebeck W, Bourguet E: Neutrophil elastase as a target in lung cancer. Anticancer Agents Med Chem 2012, 12:565-579.
137. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, et al: Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 2010, 16:219-223.
138. Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, Matziari M, Yiotakis A, Dive V: Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 2005, 87:393-402.
139. Fridman JS, Caulder E, Hansbury M, Liu X, Yang G, Wang Q, Lo Y, Zhou BB, Pan M, Thomas SM, et al: Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 2007, 13:1892-1902.
140. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, et al: EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22:304-317.